Ionis Pharmaceuticals IONS Proceeds From Real Estate Transaction
Proceeds From Real Estate Transaction at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:ProceedsFromRealEstateTransaction.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's proceeds from real estate transaction.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's proceeds from real estate transaction?
- Ionis Pharmaceuticals (IONS) reported proceeds from real estate transaction of $0 in Q4 2025.
- What is the long-term trend for Ionis Pharmaceuticals's proceeds from real estate transaction?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's proceeds from real estate transaction has grown at a -100.0% compound annual growth rate (CAGR), from $32.35M to $0.
- What does proceeds from real estate transaction mean?
- Cash received from selling real estate assets.
- How do you interpret proceeds from real estate transaction?
- An increase indicates a strategic shift in asset utilization or a need to bolster cash positions through asset sales.
- How does proceeds from real estate transaction compare across companies?
- Occasional, non-recurring event for most R&D-focused companies.